Pay in 4 interest-free payments of $5.99 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
The dual GIP/GLP-1 approach is what set tirzepatide apart from the earlier single-target GLP-1 agonists
:max_bytes(150000):strip_icc()/Health-GettyImages-2153927815-0bf99cd73e2c46908d7fc0973739f6d0.jpg)
Supplied strictly for laboratory research use only, and not approved by any regulatory authority anywhere
actual product may vary US Name: BPC-157 Alternative Names: BPC-157 Active Ingredients: BPC 157 Brand Manufacturer: Manufacturer Location: USA Click here to view Product Insert Click here to view Product Insert Click here to view Product Insert For visual reference only
The C-terminal domain contributes, together with the N-terminal domain, to shaping the co-substrate binding site, which is termed H-site, from the hydrophobic nature of co-substrates
Health regulatory agencies such as the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency of Japan (PMDA) evaluate data from clinical trials before approving the use of GLP-1 analogs for the treatment of diabetes and obesity
Expression and prognostic impact of XIAP expression in acute myelogenous leukemia (AML)
US$ 29.31
US$ 21.45
US$ 29.81
US$ 28.45
US$ 24.00
US$ 25.17
US$ 22.28
US$ 28.60
US$ 22.08
